Skip to main content
All lobbying filings

Artemis Policy Group LLC

Artemis Policy Group LLC filed a Q3 report for The Hemophilia Alliance on October 19, 2026, reporting $30,000 in lobbying income.

Lobbying for The Hemophilia Alliance · Nonprofit membership organization for federally-funded hemophilia treatment centers

As filed: ARTEMIS POLICY GROUP LLC for THE HEMOPHILIA ALLIANCE.

All filings by Artemis Policy Group LLC · Everything The Hemophilia Alliance has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 19, 2026
Income
$30,000
What the client paid this registrant for the period.
Client based in
Pennsylvania

Official filing document

 Lobbyists on this filing 1
  • JOHANNA GRAY
    Previously held: Intern, Senator Barack Obama

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 4

Issues related to reimbursement for hemophilia services and treatments in Medicare: comments on proposed HOPPS rule (CMS-1850-P) Issues related to reimbursement for hemophilia services and treatments in Medicaid Implementation of H.R. 1, One Big Beautiful Bill Act Implementation of Medicaid Community Engagement requirements: comments on Medicaid community engagement IFR (CMS-2454-IFC)

Implementation of H.R. 1, One Big Beautiful Bill Act Affordable Care Act implementation Coverage of hemophilia treatments and services in private insurance plans: comments on essential health benefits review, RIN 0938-AW02 Policies related to co-pay accumulators and maximizers, including the HELP Copays Act (S 864, HR 6423) Policies related to the operations of pharmacy benefits managers Private insurance policies that discriminate coverage for high-cost drugs and use of patient assistance programs, also known as Alternative Funding Programs

Issues related to participation in the 340B Drug Discount Program Polices related to PBMs and drug cost transparency 340B Drug Pricing Integrity and Affordability for Patients Act discussion draft SECURE 340B Act, HR 9599 SUSTAIN 340B Act, S. 5244 Comments on Senate Finance Committee RFI on drug pricing

Funding for federal hemophilia programs at CDC and HRSA for FY27 Funding and staffing for the CDC Division of Blood Disorders and Public Health Genomics: Letter to CDC Director Erica Schwartz re Division of Blood Disorders & Public Health Genomics

 Bills named in this filing 4

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem